You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, November 2016
|
| DOI | 10.1186/s40425-016-0180-7 |
| Pubmed ID | |
| Authors |
Brian I. Rini, David F. McDermott, Hans Hammers, William Bro, Ronald M. Bukowski, Bernard Faba, Jo Faba, Robert A. Figlin, Thomas Hutson, Eric Jonasch, Richard W. Joseph, Bradley C. Leibovich, Thomas Olencki, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins |
| Abstract |
Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor metabolism, inhibiting the mammalian target of rapamycin (mTOR). Additionally, a new class of immunotherapy agents, immune checkpoint inhibitors, is emerging and will play a significant role in the treatment of patients with RCC. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a Task Force, which met to consider the current role of approved immunotherapy agents in RCC, to provide guidance to practicing clinicians by developing consensus recommendations and to set the stage for future immunotherapeutic developments in RCC. |
X Demographics
The data shown below were collected from the profiles of 74 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 30 | 41% |
| Spain | 6 | 8% |
| Mexico | 5 | 7% |
| Canada | 2 | 3% |
| United Kingdom | 1 | 1% |
| India | 1 | 1% |
| France | 1 | 1% |
| Tanzania, United Republic of | 1 | 1% |
| Turkey | 1 | 1% |
| Other | 1 | 1% |
| Unknown | 25 | 34% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 47 | 64% |
| Scientists | 12 | 16% |
| Practitioners (doctors, other healthcare professionals) | 11 | 15% |
| Science communicators (journalists, bloggers, editors) | 3 | 4% |
| Unknown | 1 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 4% |
| Unknown | 52 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 13% |
| Student > Master | 7 | 13% |
| Student > Doctoral Student | 6 | 11% |
| Other | 5 | 9% |
| Student > Bachelor | 4 | 7% |
| Other | 10 | 19% |
| Unknown | 15 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 39% |
| Agricultural and Biological Sciences | 4 | 7% |
| Nursing and Health Professions | 4 | 7% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Immunology and Microbiology | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 20 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 518. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2019.
All research outputs
#49,681
of 25,734,859 outputs
Outputs from Journal for Immunotherapy of Cancer
#6
of 3,498 outputs
Outputs of similar age
#978
of 312,891 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 33 outputs
Altmetric has tracked 25,734,859 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,498 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,891 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.